NCT04873492 From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
| NCT ID | NCT04873492 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nantes University Hospital |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2022-01-24 |
| Primary Completion | 2029-07-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 130 participants in total. It began in 2022-01-24 with a primary completion date of 2029-07-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
Eligibility Criteria
Inclusion Criteria : Common criteria for retrospective MS patients: * Patients aged 18 years or older * Clinical isolated syndrome (CIS) with or without dissemination in space * Patients affiliated to an appropriate health insurance Criteria for Aggressive MS group • Start of a 2nd line therapy within the two years following the CIS Criteria for Non aggressive MS group * No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or * Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years. * Have a minimum of least 2 years of follow-up. Healthy volunteers * Aged 18 years or older * No history of clinically isolated syndrome or MS Pairing criteria : * Age +/- 5 years * Sex Prospective MS Patients * Patients aged 18 years or older * Clinical isolated syndrome (CIS) with or without dissemination in space * Patients affiliated to an appropriate health insurance Exclusion Criteria : * Ongoing participation to a another study * Refusal to genetic analyses * Immunosuppressive drug at the time of blood collection * Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample * Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard) * Pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04873492 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04873492 currently recruiting?
Yes, NCT04873492 is actively recruiting participants. Contact the research team at david.laplaud@chu-nantes.fr for enrollment information.
Where is the NCT04873492 trial being conducted?
This trial is being conducted at Nantes, France.
Who is sponsoring the NCT04873492 clinical trial?
NCT04873492 is sponsored by Nantes University Hospital. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.